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Dear Editor, 
The paper by Silva et al. provides food for thought (1). We appreciate the effort 
made in studying 612 female volunteers but question several aspects. The 
authors discuss bacterial vaginosis (BV) but it seems that they did not 
determine its existence or prevalence. This is a flaw because the organisms of 
Mycoplasma hominis and the Ureaplasma spp. are known to multiply several 
thousand-fold in BV and may affect and/or be responsible for some of the 
results presented. Furthermore, the data are qualitative and not quantitative, so 
that the existence of large numbers that might suggest pathogenic potential or 
give a clue to the diagnosis of BV cannot be provided. Of greater worry, 
however, is the conclusion by the authors that "testing for genital infections in 
reproductive-age women is of great significance, to identify the simultaneous 
presence of of different microorganisms and to inform appropriate management 
in specific situations"--and by implication, genital mycoplasmas and 
ureaplasmas. Asymptomatic carriage of these microorganisms is commonly 
found without disease developing in the majority of women, and treatment of 
M.hominis and/or ureaplasma-positive individuals has not been shown to be of 
benefit (2). Over-testing and over treatment may induce patient alarm and 
serious costs to individuals and society. A recent position statement from the 
European STI Guidelines Editorial Board specifically reviews cervicitis, PID, 
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ectopic pregnancy and infertility and concludes that there is no current evidence 
that more good than harm is done by detecting and subsequently treating 
M.hominis, Ureaplasma parvum and U.urealyticum (2).
Routine testing of asymptomatic or symptomatic women is not recommended. 
Indeed, extensive testing for these bacteria, their detection and subsequent
antimicrobial treatment may result in antimicrobial resistance in them as well as 
in 'true' STI agents, such as Neisseria gonorrhoeae and Mycoplasma
genitalium, with substantial economic costs for society and individuals, 
particularly women (2,3). It should be emphasized that if the occasion arises, 
physicians faced with a positive result for M.hominis or the Ureaplasma spp. 
should not flinch; antimicrobial treatment is not an option.
We do agree with Silva et al. that further studies are needed for better 
clarification of the clinical significance of these microorganisms, on acquisition
of other STIs and their impact on pregnancy outcomes. It is important that such 
studies control for age, sexual behaviour (number and change of sexual 
partners), use quantitative molecular diagnostic tests determining bacterial 
load, bacterial vaginosis and microscopy to evaluate inflammation 
(polymorphonuclear leucocytes),distinguish U.urealyticum and U.parvum and 
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exclude traditional sexually transmitted organisms such as N.gonorrhoeae, 
C.trachomatis, M.genitalium and trichomoniasis (2). It may not be possible to 
fulfill Koch's original postulates for proving a bacterium is the cause of a 
disease, but satisfying other criteria that have been suggested (4) should be 
within grasp. Evolving our expert guidance as to when tests become clinically 
useful, as well as for research purposes is a key responsibility. The public now 
have direct access to commercial tests for genital mollicutes, so our guidance 
can help the public and doctors alike. We believe that guiding what not to test 
for is as important as what to test for. These are crucial matters that cannot be 
tackled in a trivial way, especially when emerging antibiotic resistance is a 
critical risk.
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